News & Updates
Filter by Specialty:
SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy
Combination treatment with glucocorticoid (GC) plus hydroxychloroquine appears to yield more favourable outcomes than GC alone in the treatment of systemic lupus erythematosus (SLE) rash, while having a good safety profile, according to a study.
SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy
16 Sep 2023
COSMIC-313 highlights benefit of triplet regimen in RCC
In the COSMIC-313 trial, the addition of the tyrosine kinase inhibitor (TKI) cabozantinib to the immune checkpoint inhibitor (ICI)-doublet regimen comprising nivolumab and ipilimumab (NIVO/IPI) improved progression-free survival (PFS) in patients with previously untreated, advanced renal-cell carcinoma (RCC) who had intermediate or poor prognostic risk according to the IMDC* category.
COSMIC-313 highlights benefit of triplet regimen in RCC
15 Sep 2023
Is it safe to take olmesartan in combination therapy for advanced hypertension?
Use of olmesartan in combination practice is safe and results in similar cardiovascular composite outcomes, including myocardial infarction (MI), when compared with active comparators in hypertensive patients who need more than two antihypertensive medications, reports a study.